Session

24.09.2021     13:00–14:00

Titel:
Joint GSCN
Basic Stem Cell Research
Art:
Vortragssitzung
Raum:

24.09.2021
13:00–14:00

Titel:
Joint GSCN
Basic Stem Cell Research
Art:
Vortragssitzung
Raum:


13:00–13:20
VS-22-2 Learning regenerative strategies from regenerative animals
Elly Tanaka (Wien/AT)
Redezeit: 15 + 5 min
In contrast to the limited regeneration capabilities of humans, some animals can remarkably regenerate entire parts of the body. Salamanders can regenerate their limbs and spinal cord accurately with restoration of function. We have been studying the stem cells that execute salamander limb regeneration and the signals that induce them to restore the limb. I will discuss the injury-induced signals that coax fibroblasts to dedifferentiate into multipotent mesenchymal limb bud progenitors. When we examine fibroblasts from non-regenerative organisms such as the adult frog, we find that they are intrinsically limited in their dedifferentiation capacities.


13:20–13:40
VS-22-1 Turning blood into brain: Biomedical applications of cellular reprogramming
Frank Edenhofer (Innsbruck/AT)
Redezeit: 15 + 5 min
Cellular reprogramming holds immense potential for disease modeling and regenerative medicine. Transcription factor-driven reprogramming of somatic cells has been shown to enable derivation of patient-specific induced pluripotent stem cells (iPSCs) as well as somatic cells including neurons, cardiomyocytes and hepatocytes. Recently, we demonstrated the direct conversion from skin-derived fibroblasts and peripheral blood monocytes into induced neural stem cells (iNSCs). Here, we present a strategy to robustly derive safe, scalable human iNSC cultures and their biomedical application to induce recovery in animal models of central nervous system diseases. We investigated whether iNSCs have the ability to regulate the immunometabolic components underpinning neuroinflammation. We identified a new mechanism by which transplanted iNSCs counteract CNS-compartmentalized chronic inflammation. The presentation will outline not only hopes but also challenges in the clinical application of reprogrammed stem cells and discuss the high potential for cell therapy, disease modeling, and drug screening.


13:40–14:00
VS-22-3 Translating tissue engineered heart repair
Wolfram-Hubertus Zimmermann (Göttingen/DE)
Redezeit: 15 + 5 min
Tissue engineered heart repair with engineered human myocardium (EHM) has been translated recently into clinical testing (BioVAT-HF-DZHK20 Early Clinical Trial). The critical non-clinical in vitro and in vivo work, which informed translation from bench-to-bed, will be discussed. This includes cell production form induced pluripotent stem cells and tissue engineering of EHM according to GMP and regulatory requirements as well as late preclinical testing in non-human primates.